Introduction
Chronic bronchitis (CB) is very often associated with airflow obstruction and is especially frequent in smokers, is considered to contribute to the airway mucus hypersecretory component of Chronic Obstructive Pulmonary Disease (COPD) [1] , and is associated with considerable morbidity and high health-care costs [2] . Patients with chronic bronchitis and COPD suffer from recurrent exacerbations, with an increase in volume and/or purulence of sputum, cough and dyspnoea which contribute to progressive clinical deterioration and account for a significant proportion of the cost of caring for such patients [3, 4, 5] .
There is evidence for inflammatory and morphological changes in the airways associated with loss of ciliary function and mucus gland hyperplasia, and the importance of mucus in contributing to airflow limitation and disease progression are underscored by recent studies [6, 7] .
The use of mucolytics as adjunctive treatment of both stable and exacerbated CB/COPD has been proposed to improve disease outcome, although the value of the use of such drugs is still considered uncertain [8] .
Erdosteine is a a drug approved for the treatment of acute and chronic pulmonary diseases for more than 10 years which has been shown to improve sputum rheology in patients with mucus hypersecretion through an active metabolite (Met-I) having free thiol groups [9] . Although a few studies have been published showing that CB/COPD patients may benefit from erdosteine, marked differences in the perception of its usefulness still remain.
The aim of the present systematic review is therefore to test the available evidence that erdosteine treatment in patients with CB/COPD may be effective and accompanied by clinically relevant improvements.
Methods
This systematic review was performed in accordance with the Quality of Reporting of meta-analyses (QUORUM) guidelines [10] . 
Types of studies
Randomized controlled trials (RCTs) focusing on the comparison between erdosteine and placebo or mucolytics which reported data on efficacy and safety after 7-10 days of treatment, were used for this meta-analysis.
Types of patients
Adults patients having a medical history of chronic bronchitis (CB), generally defined as the presence of cough and sputum production for at least three months a year over two consecutive years were included in the studies used in this meta-analysis. The three largest studies also included evidence for airway obstruction, defined as an FEV 1 /FVC ratio at least 10% below the normal theoretical value [11, 12, 13] .
Patients were enrolled either at occurrence of an acute exacerbation or during the stable phase of the disease. The diagnosis of acute exacerbations was based on the occurrence of increased mucopurulent sputum, cough and fever.
Three studies additionally included the isolation of antibiotic-sensitive bacterial strains in sputum [11, 14, 15] . In two studies the inclusion of patients with hypersecretory acute bronchitis was also allowed [15, 16] .
Type of intervention
Erdosteine (300 mg capsule) was administered two or three times daily on top of background therapy, generally antibiotics and bronchodilators (beta 2agonists and aminophyllines) in patients with acute exacerbations, and bronchodilators in those with stable disease.
Placebo or mucolytics (ambroxol, N-acetylcysteine, carbocysteine, sobrerol) were administered with the same dosing schedules as erdosteine (i.e. two or three times daily) on top of background treatments.
Type of outcome measures
The following outcomes were investigated: i) cumulative global efficacy index (cGEI), the sum of all assessed respiratory symptom scores, ii) respiratory individual symptom scores (cough frequency and intensity, sputum viscosity and purulence, difficulty to expectorate, catarrh rhonchi at auscultation, dyspnoea), iii) overall assessment of efficacy (OA) by the Investigator, and
frequency of adverse events. In the original studies, similar scoring systems were used for patient self-assessment of symptoms, usually categorised on a 0-3 scale from 0= absent to 3= worst. In all the studies, safety was evaluated in terms of incidence of adverse events reported during treatment, with particular regard to gastrointestinal complaints.
Study Search
Literature was search systematically for relevant clinical trials with no language restrictions (Pub Med, Google Scholar and Scirus with search terms "chronic bronchitis", "COPD" and "acute exacerbations" combined with "erdosteine"). 
Data extraction
For each of the selected trials, the following information was retrieved: first author, publication year, details of study design, studied treatments (type of drug, schedule, duration), patient characteristics (total number, age and sex distribution, number randomised and number included in the analysis), study endpoints, occurrence and type of adverse events.
The quality of the selected trials was assessed according to a five-point validated scale [19] measuring a range of factors that impact the quality of a trial: randomization methods, blinding and description of withdrawals and drop-outs. Two independent reviewers assessed the quality of the trials to be included. Differences in the evaluation were resolved by consensus, referring back to the original article/report.
Statistical analysis
Trials were grouped according to the type of erdosteine comparator (active or placebo), study quality (Jadad scale score 1-2 vs. 3-4-5) and whether the study was published or not.
The summary measure for the respiratory individual symptom scores, as well as for the c-GEI, was the difference between changes from baseline and the end of treatment mean values calculated in the two treatment arms.
For comparison of OA of the efficacy of erdosteine versus active or placebo group, events of interest were considered under the categories good, excellent or positive.
Global estimates of the effect of treatments over time on the selected outcomes and the corresponding 95% confidence intervals (CIs) were calculated using the inverse variance method for continuous variables and the Mantel-Haenszel method for dichotomous variables. Occurrence of adverse events was analysed descriptively.
All statistical analyses were made using SAS statistical software version 9.1 (SAS Institute Inc., Cary, NC, USA) and the software ' REVMAN 4.2' provided by the Cochrane Collaboration.
Results

Study selection
Thirty-one potentially relevant studies conducted in patients with CB/COPD were retrieved. The study selection process is presented in Fig. 1 [36, 37] . Therefore, 15 RCTs were included in the final analysis.
Study characteristics
The main characteristics of the 15 selected RCTs which enrolled 1046 adult patients are summarized in Table 1 .
Six studies involving 587 patients were randomized, double-blind trials 
Study quality
We characterized the studies according to a set of factors that reflect their methodological rigor. Overall, most studies were considered of good quality in that they were prospective, randomized, double-blind trials. Only 2 [14, 16] were not randomized and 3 [16, 18, 38] were single-blind studies. When applicable, the reasons for early withdrawal were adequately described. Table 2 summarizes the results of the study quality assessment.
Patient characteristics
The 
Information related to the patients included in the eligible RCTs is presented
in Table 3 .
Outcomes
In the 1046 patients included in the analysis, erdosteine induced a significant reduction of cGEI versus comparators (-1.02; 95% CI: from -1.60
to -0.44; p = 0.0006). A higher effect was observed in comparison to placebo (-1.41; 95% CI: from -2.49 to -0.33; p = 0.01), although the reduction was also significant vs. active comparators (-0.66; 95% CI: from -1.30 to -0.02; p = 0.04) ( Fig. 2) .
Data on cough frequency and intensity were available in 13 and 11 RCTs, respectively (972 and 496 participants). Erdosteine positively impacted on cough frequency overall (-0.19; 95% CI: from -0.34 to -0.03; p = 0.02) and achieved significance vs. placebo (-0.23; 95%CI: from -0.47 to 0.00; p = 0.05) ( Fig. 3 ). With regard to cough intensity, the effect of erdosteine was significant overall (-0.30; 95% CI: from -0.44 to -0.17; p < 0.00001), vs.
placebo (-0.42; 95% CI: from -0.75 to -0.08; p = 0.01) and mucolytics (-0.26; 95% CI: from -0.43 to -0.10; p = 0.002). Data regarding sputum viscosity and purulence were reported in 8 and 12 RCTs, respectively (812 and 946 participants). Erdosteine positively impacted on sputum viscosity overall (-0.28; 95% CI: from -0.49 to -0.07; p = 0.008) and vs. placebo (-0.27; 95% CI: from -0.51 to -0.03; p = 0.03), but not on sputum purulence (-0.11; 95% CI: from -0.28 to 0.07; p = 0.25). Data on expectoration difficulty were available in 13 RCTs involving 992 patients. Erdosteine significantly improved this symptom overall (-0.24; 95% CI: from -0.40 to -0.08; p = 0.004) and vs. mucolytics (-0.19; 95% CI: from -0.34 to -0.03; p = 0.02) with nearly significant difference being achieved vs. placebo (-0.29; 95% CI: from -0.60 to 0.03; p = 0.07), as presented in Fig. 4 . The symptoms of catarrh ronchi at auscultation and dyspnoea were evaluated in 8 and 6 RCTs, respectively, involving 469 and 744 patients. The presence of catarrh ronchi at auscultation was significantly reduced by erdosteine (-0.35; 95% CI: from -0.60 to -0.10; p = 0.006), while the effects on dyspnoea were only significant vs. placebo (-0.17; 95% CI: from -0.30 to -0.05).
Outcome data related to individual respiratory symptom scores are shown in 
Statistical analyses did not suggest potential bias either for study quality and for whether a study was published or not (data not shown).
Safety profile
All treatments were well tolerated. Adverse events were reported by 54 patients (10.2%) in the erdosteine group and in 57 patients (11.0%) in the reference groups. The most frequently occurring adverse events were gastrointestinal complaints, in particular nausea, epigastric pain or heartburn, diarrhoea or loose stool. Only one patient treated with erdosteine reported taste loss, and allergic reactions occurred in 3 patients treated with erdosteine and in 3 with reference treatments. A summary of reported adverse events is presented in Table 5 .
Discussion
The When considering the two studies conducted in patients with stable CB/COPD [12,40], the benefit provided by erdosteine on cough and sputum scores was less evident, presumably due to the short duration of treatment in these studies. It should be noted however, that in another study, not considered for the present review, a more prolonged treatment of 28 days significantly improved chronic symptoms of cough and sputum in stable CB patients [33] . In the comparative studies vs. placebo, a significant effect on dyspnoea was also shown, suggesting that a facilitated mucus clearance with erdosteine has the potential to translate into improved quality of life for patients with CB. On the other hand, erdosteine was no more active on sputum purulence scores compared to antibiotic monotherapy, a finding that is perhaps not surprising given the major efficacy of antibiotics on this feature of exacerbations, rather than mucolytics. 
Figure 2
Comparison of erdosteine versus placebo and other mucolytics. Outcome: Cumulative Global Efficacy Index (cGEI)
Figure 3
Comparison of erdosteine versus placebo and other mucolytics. Outcome: Cough frequency
Figure 4
Comparison of erdosteine versus placebo and other mucolytics. Outcome: Difficulty to expectorate 
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